All In Biotech

Drug Trial Radar · NCT05486182

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Patients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

153

Actual

Start

Feb 8, 2022

Primary completion

Apr 18, 2025

Study completion Dec 26, 2025

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
Simbec-Orion Group; Keosys
First posted
Aug 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC). Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria. After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the investigators to evaluate the initial management plan. Patient will perform the ESTROTEP PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be completed by the investigators. Patients will be followed for 12 months to evaluate their clinical status and standard of care investigations.

Conditions

  • Metastatic Breast Cancer

Interventions

  • 18F Fluoroestradiol Radiopharmaceutical with PET/CTDrug

    Administration of one dose of 18F FES for PET/CT imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.Time frame: Change from baseline therapeutic measure at 15 days after ESTROTEP PET/CT

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • CGFL

    Dijon, France

  • CHU Grenoble Alpes

    La Tronche, France

  • CHU de Limoges - Dupuytren

    Limoges, France

  • Centre Léon Bérard

    Lyon, France

  • Institut du Cancer de Montpellier

    Montpellier, France

  • Hôpital Américain de Paris

    Neuilly-sur-Seine, France

  • Centre Antoine Lacassagne

    Nice, France

  • Hôpital Tenon

    Paris, France

  • Institut Curie

    Paris, France

  • Institut Curie

    Saint-Cloud, France

  • Institut Claudius Regaud Centre de Lutte Contre le Cancer

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.